Jupiter Neurosciences (JUNS) Operating Income (2023 - 2025)
Jupiter Neurosciences (JUNS) posted quarterly Operating Income of -$2.8 million for Q4 2025, down 92.6% year-over-year from -$38.0 million in Q4 2024, and down 22.28% quarter-over-quarter from -$2.3 million in Q3 2025.
Jupiter Neurosciences (JUNS) Operating Income (2023 - 2025) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Operating Income for 3 consecutive years, with -$2.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Operating Income fell 92.6% year-over-year to -$2.8 million; the TTM figure through Dec 2025 stood at -$8.9 million (down 189.27% YoY), while the FY2025 annual figure was -$8.9 million, down 188.19% from the prior year.
- Operating Income declined to -$2.8 million in Q4 2025 per JUNS's latest filing, from -$2.3 million in the prior quarter.
- Across five years, Operating Income topped out at -$493547.0 in Q3 2024 and bottomed at -$2.8 million in Q4 2025.
- Historically, Operating Income has averaged -$1.4 million across 3 years, with a median of -$1.5 million in 2023.
- Annual changes were most pronounced in 2024 — Operating Income surged 65.78% — and 2025, when it tumbled 365.42%.
- Jupiter Neurosciences' Operating Income stood at -$535642.0 in 2023, then sank by 172.26% to -$1.5 million in 2024, then sank by 92.6% to -$2.8 million in 2025.
- Business Quant data shows JUNS's Operating Income at -$2.8 million in Q4 2025, -$2.3 million in Q3 2025, and -$2.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.91 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.87 Bn | 59.68 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.18 Bn | 53.04 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.96 Bn | 36.87 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.23 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 27.79 Bn | 9.40 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.37 Bn | 26.53 Bn | - | 133.12 Mn |
| 10 | Jupiter Neurosciences | 3.50 Mn | 1.97 Mn | 21,064.00 | -2.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.81 Mn |
| Sep 30, 2025 | -2.30 Mn |
| Jun 30, 2025 | -2.26 Mn |
| Mar 31, 2025 | -1.54 Mn |
| Dec 31, 2024 | -1.46 Mn |
| Sep 30, 2024 | -493,547.00 |
| Jun 30, 2024 | -557,077.00 |
| Mar 31, 2024 | -570,695.00 |
| Dec 31, 2023 | -535,642.00 |
| Sep 30, 2023 | -1.44 Mn |